ZFP36L2 and cardiomyopathy: To determine whether the postpartum cardiomyopathy associated with Zfp36l2 deletion is due to its specific effects on the mTORc1 pathway and its hyperactivation, we treated female pregnant mice with 1 mg/kg subcutaneous rapamycin every other day in the third trimester of the first pregnancy (Supplemental Figure 15A).